Solid Tumor Panel NGS Genetic Test
At DNA Labs UAE, we offer the Solid Tumor Panel NGS Genetic DNA Test at a cost of AED 4400.0. This test utilizes next-generation sequencing (NGS) technology to analyze the genetic makeup of solid tumors. By identifying mutations and other genetic alterations, this test can assist in making informed treatment decisions and improving patient outcomes.
Test Details
The Solid Tumor Panel NGS Genetic DNA Test is a diagnostic test that analyzes the genetic composition of solid tumors using NGS technology. This test is particularly beneficial for patients with lung cancer, breast cancer, colon cancer, and melanoma. The specific genes included in the panel may vary depending on the laboratory performing the test and the type of tumor being analyzed.
Sample Collection
To perform the test, a sample of tumor tissue is collected from the patient through a biopsy or surgical procedure. The DNA in the tumor cells is then extracted and sequenced using NGS technology.
Test Results
The results of the Solid Tumor Panel NGS Genetic DNA Test provide valuable information for oncologists. By identifying mutations, copy number variations, and other genetic alterations, the test helps tailor treatment plans to the specific genetic profile of the patient’s tumor. If a mutation is found in a gene that responds to targeted therapy, the patient may be a suitable candidate for that treatment. The test also provides insights into the patient’s prognosis and risk of recurrence, assisting in long-term care and surveillance.
Pre-Test Information
Prior to the test, it is important to provide the clinical history of the patient who is going for the Solid Tumor Panel NGS Genetic DNA Test. Additionally, a genetic counseling session is conducted to draw a pedigree chart of family members affected by specific genes associated with solid tumors, such as ABL1, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARID1A, and many others.
Report Delivery and Test Department
The report delivery time for the Solid Tumor Panel NGS Genetic DNA Test is approximately 3 to 4 weeks. This test falls under the Genetics department and is typically requested by oncologists.
Conclusion
The Solid Tumor Panel NGS Genetic DNA Test offered at DNA Labs UAE is a valuable diagnostic tool for analyzing the genetic makeup of solid tumors. By identifying mutations and other genetic alterations, this test assists in making informed treatment decisions, improving patient outcomes, and providing insights into prognosis and risk of recurrence. For a cost of AED 4400.0, this test is performed using NGS technology and requires a sample of tumor tissue collected through a biopsy or surgical procedure.
| Test Name | Solid tumor panel NGS Genetic DNA Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for Solid tumor panel NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ABL1, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARID1A, ASXL1, ATM, ATR, ATRX, AXL, BAP1, BRAF, BRCA1, BRCA2, BTK, CBL, CCND1, CDH1, CDK12, CDK4, CDK6, CDKN1B, CDKN2A, CDKN2B, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FANCA, FANCD2, FANCI, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3-3A, H3C2, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KMT2A, KMT2C, KMT2D, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MEN1, MET, MLH1, MPL, MRE11, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3R1, PMS2, POLE, PPP2R1A, PTCH1, PTEN, PTPN11, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAF1, RB1, RBM10, RET, RHEB, RHOA, RIT1, RNF43, ROS1, SETD2, SF3B1, SLX4, SMAD4, SMARCA4, SMARCB1, SMO, SPOP, SRC, STAT3, STK11, TERT, TOP1, TP53, TSC1, TSC2, TSHR, U2AF1, VHL, XPO1 |
| Test Details |
The solid tumor panel NGS genetic DNA test is a diagnostic test that uses next-generation sequencing (NGS) technology to analyze the genetic makeup of solid tumors. This test can identify mutations and other genetic alterations that may be driving the growth and spread of the tumor, which can help guide treatment decisions and improve patient outcomes. The solid tumor panel NGS genetic DNA test typically analyzes a panel of genes that are commonly associated with solid tumors, such as lung cancer, breast cancer, colon cancer, and melanoma. The specific genes included in the panel may vary depending on the laboratory performing the test and the type of tumor being analyzed. To perform the test, a sample of tumor tissue is collected from the patient through a biopsy or surgical procedure. The DNA in the tumor cells is then extracted and sequenced using NGS technology. The resulting data is analyzed to identify mutations, copy number variations, and other genetic alterations that may be relevant to the patient’s cancer. The results of the solid tumor panel NGS genetic DNA test can help oncologists tailor treatment to the specific genetic profile of the patient’s tumor. For example, if the test identifies a mutation in a gene that is known to respond to a particular targeted therapy, the patient may be a good candidate for that treatment. Additionally, the test can provide information about the patient’s prognosis and risk of recurrence, which can help guide long-term care and surveillance. |
